SHR2285 tablet

DRUG3 trials

Sponsors

Jiangsu HengRui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.

Conditions

Prevention of Venous Thrombosis After TKAThrombosisThrombus

Phase 1

The Multiple Dose of PK/PD Study of SHR2285 Tablets in Healthy Subjects

CompletedNCT04229433

Jiangsu HengRui Medicine Co., Ltd.Thrombus

Start: 2020-08-11End: 2020-11-08Updated: 2021-05-25

The Single, Multiple Dose and Food Effect Study of SHR2285 Tablets on Pharmacokinetics and Pharmacodynamics in Healthy Subjects

CompletedNCT04472819

Jiangsu HengRui Medicine Co., Ltd.Thrombosis

Start: 2020-08-28End: 2021-05-31Updated: 2021-09-28

Phase 2

Clinical Study on the Efficacy and Safety of Multiple Oral Administrations of SHR2285 Tablets in Patients Undergoing Elective Total Knee Arthroplasty

TerminatedNCT05203705

Shanghai Hengrui Pharmaceutical Co., Ltd.Prevention of Venous Thrombosis After TKA

Start: 2022-03-07End: 2023-03-14Updated: 2025-11-17

Related Papers

The Safety, Pharmacokinetics, and Pharmacodynamics of SHR2285, an Oral Small Molecule Factor XIa Inhibitor, in Healthy Chinese Volunteers.

2023-06-162 citations